Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Five scientists named recipients of Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2012 recipients of the Damon Runyon-Rachleff Innovation Award.

24 Jan 2012

EntreMed announces $10 million in financing from strategic accredited investors

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has secured $10 million in financing with strategic accredited investors, including IDG-Accel China Growth Fund II L.P., Emerging Technology Partners, LLC, and Dr. Tak W. Mak, Director of The Campbell Family Institute for Cancer Research.

23 Jan 2012

UHCMC now offers HITEC for women with gynecologic cancers

Patients with gynecologic cancer have new hope in a novel technology now offered at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center. A team of cancer specialists, led by Robert DeBernardo, MD, is among the first in the nation to launch a dedicated program using Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat ovarian, endometrial and select other cancers.

21 Jan 2012

LabCorp announces nationwide availability of Risk of Ovarian Malignancy Algorithm

Laboratory Corporation of America Holdings announced today the nationwide availability of a new FDA cleared risk stratification tool (ROMA, Risk of Ovarian Malignancy Algorithm) that combines the results for Fujirebio HE4, Abbott's ARCHITECT CA 125 II, and menopausal status into a numerical score that, along with clinical and radiological evaluation, can aid in evaluating whether a woman over the age of 18 who presents with an ovarian mass and for whom surgery is planned is at high or low likelihood of finding malignancy on surgery.

19 Jan 2012

Innovative computer algorithm identifies clinically prognostic marker for cancer

Researchers at the Stanford University School of Medicine have used an innovative mathematical technique to find markers that effectively predict how deadly a cancer will be. The discovery, which in this case concerned bladder cancer, could lead to faster, less expensive and more accurate analysis of cancer risk and better treatment of the disease.

18 Jan 2012

Scientists identify rare genetic mutation linked to prostate cancer

After a 20-year quest to find a genetic driver for prostate cancer that strikes men at younger ages and runs in families, researchers have identified a rare, inherited mutation linked to a significantly higher risk of the disease.

12 Jan 2012

Inherited breast and ovarian cancer drug trial re-launched in tablet form

Cancer Research UK's Drug Development Office has re-launched a trial of a promising drug to treat inherited breast and ovarian cancer - but this time taken as a tablet by outpatients.

11 Jan 2012

Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

Circadian Technologies Limited announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre.

9 Jan 2012

Annual prostate cancer testing does not reduce mortality among men

Men enrolled in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial had no evidence of a mortality benefit compared to a control group of men undergoing usual care, according to a study published online Jan. 6 in the Journal of the National Cancer Institute.

7 Jan 2012

Annual screening tests do not decrease deaths from prostate cancer

There's new evidence that annual prostate cancer screening does not reduce deaths from the disease, even among men in their 50s and 60s and those with underlying health conditions, according to new research led by Washington University School of Medicine in St. Louis.

6 Jan 2012

State roundup: Colo. reports 'record' number of Medicaid recipients; Hollywood nursing home stymied by Congress?

Nearly 615,000 Coloradans were on Medicaid in November, by far a record high, officials said Wednesday, attributing the vast bulk of the growth to economic hard times rather than recent eligibility expansions. ... the 614,146 Coloradans enrolled in Medicaid in November represented a 57.7 percent increase over January 2007. ... roughly 13 percent of all Coloradans are covered by state health-insurance programs.

6 Jan 2012

Experts share 10 symptoms of cervical and other gynecologic cancers

Pelvic pain and abnormal bleeding aren't the only signs of gynecologic cancer. As part of Cervical Health Awareness Month in January, experts at The University of Texas MD Anderson Cancer Center share other symptoms that often are overlooked.

6 Jan 2012

New anti-tumor compounds show promise for hard-to-treat cancers

New anti-tumor compounds produced by Dr. Aleem Gangjee, Distinguished Professor of Medicinal Pharmacy at Duquesne University's Mylan School of Pharmacy, show such promise for fighting hard-to-treat tumors that the National Institutes of Health (NIH) has placed them on its fast track for development.

6 Jan 2012

New algorithm could help GPs identify women at risk of early ovarian cancer

The lives of hundreds of women could be saved every year, thanks to a simple online calculator that could help GPs identify women most at risk of having ovarian cancer at a much earlier stage.

5 Jan 2012

Avastin fails to live up to expectations for extending survival in ovarian cancer

Cancer drug Avastin has been found to add about four months to the time it takes for the cancer to worsen for women with advanced cases of ovarian cancer says a new report. However it may not extend survival significantly.

29 Dec 2011

GOG targeted therapy phase 3 clinical trial delays progression of advanced ovarian cancer

Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer.

29 Dec 2011

Bevacizumab delays disease progression in ovarian cancer

Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK.

29 Dec 2011